Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Cellular Dynamics International Inc. Stories

2013-07-10 12:27:50

MADISON, Wis., July 10, 2013 /PRNewswire/ -- Cellular Dynamics International, Inc., a developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that it has commenced an initial public offering of 3,846,000 shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission ("SEC"). In addition, the underwriters will have a 30-day option to purchase up to an...

2013-06-05 08:29:04

MADISON, Wis., June 5, 2013 /PRNewswire/ -- Cellular Dynamics International (CDI) today announced that it has expanded its MyCell® Products line, offering access to a number of human disease models and licensing key genetic engineering patents from Life Technologies and Sigma-Aldrich. CDI's MyCell Products include custom cell products manufactured using induced pluripotent stem cell (iPSC) technology to make stem cells or differentiated cells from any individual, including those with...

2013-06-04 08:29:25

MADISON, Wis., June 4, 2013 /PRNewswire/ -- Cellular Dynamics International, Inc., a developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that it has filed a registration statement on June 3, 2013, on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock. The registration statement filed on June 3, 2013, represents the Company's initial...

2013-05-24 23:04:43

Under the new agreement, CDI now can make use of, distribute, sublicense and sell cellular products that employ the licensed technology for therapeutic use. New York, NY (PRWEB) May 24, 2013 The Icahn School of Medicine at Mount Sinai has granted Cellular Dynamics International (CDI) exclusive license rights to commercially develop cardiomyocyte progenitors for in vivo cell therapy and regenerative medicine applications. These cells are capable of further differentiation into the multiple...

2013-03-21 08:30:45

MADISON, Wis., March 21, 2013 /PRNewswire/ -- Cellular Dynamics International (CDI) and Coriell Institute for Medical Research today announced receiving two multi-million dollar grant awards from the California Institute for Regenerative Medicine (CIRM). CIRM awarded CDI $16 million to create 3 induced pluripotent stem cell (iPSC) lines for each of 3000 healthy and diseased donors. Tissue samples will be taken from patients suffering from Alzheimer's disease, autism spectrum disorders,...

2013-03-08 08:23:18

MADISON, Wis., March 8, 2013 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI), a leading commercial producer of human induced pluripotent stem cell (iPSC) lines and tissue cells for drug discovery, safety, stem cell banking and cellular therapeutics, today announced scientific presentations at the Society of Toxicology's 52(nd) Annual Meeting (SOT), March 10 to 14 in San Antonio, that demonstrate the expanding utility of CDI's iCell® products on toxicology assay development....

2013-01-17 08:26:38

MADISON, Wis., Jan. 17, 2013 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI), a leading commercial producer of human induced pluripotent stem cell (iPSC) lines and tissue cells for drug discovery and safety, today announced that it is producing human iPSC master cell banks from five individual donors under current Good Manufacturing Practices (cGMPs). Manufacturing human iPSCs and ultimately human cells under cGMPs enables the possible use of iPSC-derived human cells within a...

2013-01-03 08:26:07

MADISON, Wis., Jan. 3, 2013 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI) today announced a Center of Excellence agreement with AstraZeneca to accelerate the pace of drug discovery through the use of human induced pluripotent stem cell (iPSC) lines and tissue cells. iPSC technology, based on reprogramming adult cells from a simple blood sample or a skin biopsy to a pluripotent stem cell state, shows promise in delivering robust human cell models of high utility in drug...

2012-12-18 08:27:54

CHALFONT ST. GILES, UK and MADISON, Wis., Dec. 18, 2012 /PRNewswire/ -- GE Healthcare Life Sciences, a business unit of GE Healthcare (NYSE: GE) and Cellular Dynamics International (CDI), a leading commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, announced today that GE Healthcare has licensed CDI to develop, manufacture and sell cellular assays and models derived from induced pluripotent stem (iPS) cells for use in drug discovery and toxicity...

2012-12-12 08:25:25

MADISON, Wis., Dec. 12, 2012 /PRNewswire/ -- Cellular Dynamics International (CDI), a leading commercial producer of human induced pluripotent stem cell (iPSC) lines and tissue cells, today announced the publication of research demonstrating the use of human iPSC-derived iCell® Neurons to model Alzheimer's disease (AD) and how they may be used in high throughput drug screening. This research was performed by the lab of Zhong Zhong, Ph.D., head of discovery in the regenerative medicine...